Method for composition for treatment of gastric and duodenal disorders
AssigneePharmacia Corporation
InventorsJohan Stjernschantz, Bahram Resul
Life of this patent
Estimating the term…
Abstract
The invention is related to the field of treating gastric and duodenal disorders and more specifically to the use of certain 13,14-dihydro-prostaglandin E derivatives, especially of PGE.sub.2, which are modified to contain a ring structure in the omega chain. The invention relates also to pharmaceutical compositions containing an active amount of these derivatives.
Claims20
A method for treating a person having duodenal or gastric ulcer, gastritis or related alimentary diseases comprising administering a prostaglandin derivative having the formula ##STR2## wherein R is an alkyl chain with 1-10 carbon atoms,
- RI is O or CH.sub.2,
- RII is H, OH, lower alkyl
- X is a carbon chain with 1-9atoms in the chain, optionally interrupted by one heteroatom O, N or S, and
- RIII is a ring structure selected from the group consisting of a phenyl group which is unsubstituted or has one or more substituents selected from C1-C5 alkyl groups, C1-C4 alkoxy groups, trifluoromethyl groups, C1-C3 aliphatic acylamino groups, nitro groups, halogen atoms, and a phenyl group;
- an aromatic heterocyclic group having 5-6 ring atoms;
- or
- a cycloalkane or a cycloalkene with 3-7 carbon atoms in the ring, optionally substituted with lower alkyl groups with 1-5 carbon atoms.
A composition for treating a person having duodenal or gastric ulcer, gastritis or related alimentary diseases consisting of a PGE derivative of the formula ##STR3## wherein R is an alkyl chain with 1-10 carbon atoms,
- RI is O or CH.sub.2,
- RII is H, OH, lower alkyl or halogen,
- X is a carbon chain with 1-9atoms in the chain, optionally interrupted by one heteroatom O, N or S, and
- RIII is a ring structure selected from the group consisting of
- a phenyl group which is unsubstituted or has one or more substituents selected from C1-C5 alkyl groups, C1-C4 alkoxy groups, trifluoromethyl groups, C1-C3 aliphatic acylamino groups, nitro groups, halogen atoms, and a phenyl group;
- an aromatic heterocyclic group having 5-6 ring atoms;
- or
- a cycloalkane or a cycloalkene with 3-7 carbon atoms in the ring, optionally substituted with lower alkyl groups with 1-5 carbon atoms;
- in a physiologically acceptable carrier.
Dependencies are inferred from the claim text.